Effectiveness of a screening program for hepatitis C

Digestive Diseases and Sciences

Volumn 51, Issue 5, 2006, Pages 976-981

  Cheung, Ramsey C ^a,b   Cunningham, Barbara A ^a   Cooper, Allen D ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

HCV; Outcome; Screening; Treatment

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS C ANTIBODY;

ADULT; AGED; ANTIBODY SCREENING; ARTICLE; DIAGNOSTIC KIT; DIAGNOSTIC TEST; DRUG CONTRAINDICATION; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK FACTOR; SCREENING; VIREMIA;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT ACCEPTANCE OF HEALTH CARE; RISK FACTORS; UNITED STATES; VETERANS; VIREMIA;

EID: 33745831216     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9100-x     Document Type: Article

References (13)

1. Briggs ME, Baker C, Hall R, Gaziano JM, Gagnon D, Bzowej N, Wright TL (2001) Prevalence and risk factor for hepatitis C virus infection at an urban Veterans Administration medical center. Hepatology 34:1200-1205.
2. Cheung RC (2000) Epidemiology of hepatitis C virus infection in American veterans. Am J Gastroenterol 95:740-747.
3. National Institutes of Health Consensus Development Conference Panel Statement (1997) Management of hepatitis C. Hepatology 26(Suppl 1):2S-10S.
4. EASL International consensus conference on hepatitis C (1999) Consensus statement. J Hepatol 31(Suppl 1):3-8.
5. Koff RS (1999) Cost-effectiveness of combined interferon and ribavirin versus interferon alone. Clin Liver Dis 3:827-841.
6. Zeusem S (2001) What is (cost) effective in patients with chronic hepatitis C virus infection? Eur J Gastroenterol Hepatol 13:473-476.
7. Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis in patients with chronic hepatitis C. Lancet 349:825-832.
8. Cawthorne CH, Rudat KR, Burton MS, Brown KE, Luxon BA, Janney CG, Fimmel CJ (2002) Limited success of HCV antiviral therapy in United States veterans. Am J Gastroenterol 97:149-155.
9. Falck-Ytter Y, Kate H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ (2002) Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 136:288-292.
10. VA National Hepatitis Center (1999) Treatment recommendations for patients with chronic hepatitis C (version 1). http://www.va.gov/hepatitisC.
11. National Institutes of Health Consensus Development Conference Panel Statement (2002) management of hepatitis C. Hepatology 36(Suppl 1):S3-S20.
12. Rowan PJ, Tabasi S, Abdul-latif M, Kunik ME, El-Serag HB (2004) Psychosocial factors are the most common contraindications for antiviral therapy at initial evaluation in veterans with chronic hepatitis C. J Clin Gastroenterol 38:530-534.
13. Muir AJ, Provenzale D (2002) A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C infection. J Clin Gastroenterol 34:268-271.